ProShare Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $143M | Sell |
287,847
-85,685
| -23% | -$38M | 0.21% | 110 |
|
|
2026
Q1 | $167M | Sell |
373,532
-83,514
| -18% | -$38.9M | 0.25% | 76 |
|
|
2025
Q4 | $207M | Buy |
457,046
+123,314
| +37% | +$53.2M | 0.37% | 54 |
|
|
2025
Q3 | $131M | Sell |
333,732
-67,512
| -17% | -$28.2M | 0.27% | 108 |
|
|
2025
Q2 | $179M | Buy |
401,244
+18,214
| +5% | +$8.39M | 0.36% | 77 |
|
|
2025
Q1 | $186M | Buy |
383,030
+38,504
| +11% | +$17.9M | 0.42% | 70 |
|
|
2024
Q4 | $139M | Buy |
344,526
+53,116
| +18% | +$24.6M | 0.32% | 101 |
|
|
2024
Q3 | $136M | Buy |
291,410
+21,669
| +8% | +$10.4M | 0.33% | 98 |
|
|
2024
Q2 | $126M | Sell |
269,741
-30,529
| -10% | -$13.3M | 0.34% | 99 |
|
|
2024
Q1 | $126M | Buy |
300,270
+48,699
| +19% | +$20.6M | 0.33% | 99 |
|
|
2023
Q4 | $102M | Sell |
251,571
-45,253
| -15% | -$16.7M | 0.31% | 99 |
|
|
2023
Q3 | $103M | Buy |
296,824
+35,214
| +13% | +$12.3M | 0.32% | 100 |
|
|
2023
Q2 | $92.1M | Sell |
261,610
-18,485
| -7% | -$6.23M | 0.27% | 102 |
|
|
2023
Q1 | $88.2M | Buy |
280,095
+24,813
| +10% | +$7.44M | 0.27% | 103 |
|
|
2022
Q4 | $73.7M | Sell |
255,282
-26,430
| -9% | -$8.06M | 0.26% | 99 |
|
|
2022
Q3 | $81.6M | Sell |
281,712
-48,614
| -15% | -$14M | 0.31% | 94 |
|
|
2022
Q2 | $93.1M | Sell |
330,326
-158,650
| -32% | -$42.5M | 0.31% | 96 |
|
|
2022
Q1 | $128M | Sell |
488,976
-28,213
| -5% | -$6.7M | 0.27% | 104 |
|
|
2021
Q4 | $114M | Buy |
517,189
+144,037
| +39% | +$28M | 0.22% | 116 |
|
|
2021
Q3 | $67.7M | Buy |
373,152
+33,518
| +10% | +$6.54M | 0.19% | 122 |
|
|
2021
Q2 | $68.5M | Sell |
339,634
-5,069
| -1% | -$1.06M | 0.2% | 121 |
|
|
2021
Q1 | $74.1M | Buy |
344,703
+44,967
| +15% | +$9.88M | 0.23% | 115 |
|
|
2020
Q4 | $70.8M | Buy |
299,736
+37,064
| +14% | +$8.5M | 0.26% | 109 |
|
|
2020
Q3 | $71.5M | Buy |
262,672
+34,849
| +15% | +$9.61M | 0.33% | 97 |
|
|
2020
Q2 | $66.1M | Buy |
227,823
+27,309
| +14% | +$7.4M | 0.35% | 93 |
|
|
2020
Q1 | $47.7M | Sell |
200,514
-85,641
| -30% | -$19.6M | 0.34% | 90 |
|
|
2019
Q4 | $62.7M | Buy |
286,155
+13,551
| +5% | +$2.74M | 0.29% | 90 |
|
|
2019
Q3 | $46.2M | Buy |
272,604
+4,642
| +2% | +$821K | 0.26% | 95 |
|
|
2019
Q2 | $49.1M | Sell |
267,962
-28,653
| -10% | -$5.01M | 0.29% | 93 |
|
|
2019
Q1 | $54.6M | Buy |
296,615
+27,238
| +10% | +$5.03M | 0.33% | 90 |
|
|
2018
Q4 | $44.6M | Buy |
269,377
+26,403
| +11% | +$4.57M | 0.31% | 90 |
|
|
2018
Q3 | $46.8M | Sell |
242,974
-25,163
| -9% | -$4.48M | 0.32% | 86 |
|
|
2018
Q2 | $45.6M | Sell |
268,137
-47,540
| -15% | -$7.37M | 0.31% | 90 |
|
|
2018
Q1 | $51.4M | Buy |
315,677
+37,852
| +14% | +$6.18M | 0.34% | 89 |
|
|
2017
Q4 | $41.6M | Buy |
277,825
+60,520
| +28% | +$8.96M | 0.29% | 93 |
|
|
2017
Q3 | $33M | Buy |
217,305
+15,247
| +8% | +$2.29M | 0.3% | 84 |
|
|
2017
Q2 | $26M | Sell |
202,058
-18,043
| -8% | -$2.17M | 0.26% | 86 |
|
|
2017
Q1 | $24.1M | Sell |
220,101
-52,376
| -19% | -$4.61M | 0.25% | 91 |
|
|
2016
Q4 | $20.1M | Buy |
272,477
+40,979
| +18% | +$3.33M | 0.22% | 97 |
|
|
2016
Q3 | $20.2M | Sell |
231,498
-59,671
| -20% | -$5.64M | 0.28% | 84 |
|
|
2016
Q2 | $25M | Buy |
291,169
+5,597
| +2% | +$484K | 0.32% | 87 |
|
|
2016
Q1 | $22.7M | Sell |
285,572
-18,521
| -6% | -$1.68M | 0.31% | 93 |
|
|
2015
Q4 | $38.3M | Buy |
304,093
+27,344
| +10% | +$3.3M | 0.46% | 43 |
|
|
2015
Q3 | $28.8M | Sell |
276,749
-662
| -0.2% | -$85K | 0.4% | 54 |
|
|
2015
Q2 | $34.3M | Sell |
277,411
-31,982
| -10% | -$4.03M | 0.47% | 40 |
|
|
2015
Q1 | $36.5M | Buy |
309,393
+44,162
| +17% | +$5.29M | 0.43% | 44 |
|
|
2014
Q4 | $31.5M | Buy |
265,231
+60,835
| +30% | +$6.85M | 0.37% | 54 |
|
|
2014
Q3 | $23M | Sell |
204,396
-31,473
| -13% | -$3M | 0.3% | 56 |
|
|
2014
Q2 | $22.3M | Sell |
235,869
-50,171
| -18% | -$3.52M | 0.29% | 58 |
|
|
2014
Q1 | $20.2M | Buy |
286,040
+97,403
| +52% | +$7.71M | 0.25% | 65 |
|
|
2013
Q4 | $14M | Buy |
188,637
+75,747
| +67% | +$5.28M | 0.21% | 84 |
|
|
2013
Q3 | $8.56M | Buy |
112,890
+29,930
| +36% | +$2.38M | 0.2% | 84 |
|
|
2013
Q2 | $6.63M | Buy |
+82,960
| New | +$6.11M | 0.13% | 138 |
|
Other funds holding VRTX
ProShare Advisors's VRTX Position: Q2 2026 in Review
ProShare Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 23% in Q2 2026, selling an estimated $38M and leaving 287,847 shares worth $143M. The position accounts for 0.21% of the portfolio, ranked #110.
ProShare Advisors first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $207M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- ProShare Advisors held 287,847 shares of Vertex Pharmaceuticals worth $143M as of Q2 2026.
- ProShare Advisors sold 85,685 Vertex Pharmaceuticals shares in Q2 2026, an estimated $38M.
- Vertex Pharmaceuticals made up 0.21% of ProShare Advisors's portfolio in Q2 2026, its #110 holding.
- ProShare Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- ProShare Advisors's Vertex Pharmaceuticals position peaked at $207M in Q4 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.